• Sisram reported the launch of its Alma IQ imaging platform, positioning it as part of a broader strategy to combine diagnostics with its aesthetics treatment portfolio.
• The company said the rollout supports its push to integrate AI-enabled tools across its product ecosystem, which could strengthen customer retention through more standardized workflows across clinics.
• Management also highlighted the commercialization progress of DAXXIFY in China, citing distribution volumes reaching “tens of thousands” of units as coverage expanded across multiple provinces and cities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sisram Medical Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260323-12063761), on March 23, 2026, and is solely responsible for the information contained therein.